PLAUR and chronic kidney disease: Additionally, studies have demonstrated substantial assay-related variability in soluble urokinase plasminogen activator receptor (suPAR) levels across independent CKD studies, highlighting how non-standardized analytical methods can lead to conflicting conclusions regarding biomarker utility [108].